AACR 2014: Where ‘meaningful advances’ against cancer begin
More than 18,000 researchers, clinicians, advocates and other professionals will convene at the 105th American Association for Cancer Research (AACR) annual meeting taking place in San Diego from April 5 to 9. With more than 6,000 findings being presented over this five-day period, the amount of information can seem overwhelming.
But all those posters, presentations and seminars serve a purpose, which is best summed up by the theme of this year's meeting: "Harnessing Breakthroughs –Targeting Cures."
"We are in the generation of personalized, precision medicine where we can learn a great deal about cancers," said Steven T. Rosen, M.D., City of Hope's Irell & Manella Cancer Center Director’s Distinguished Chair. "Conferences such as AACR's annual meeting lead to true dialogue, exchange of information and collaboration. This not only benefits the scientists' own research projects, but also leads to meaningful advances for treating, detecting and preventing cancers."
Added Rosen, who is also City of Hope's provost and chief scientific officer: "City of Hope investigators are well-represented at this year's annual meeting. They have made significant contributions to our understanding of cancers. This includes furthering our knowledge of individual cancers' epidemiology and etiology, developing novel therapies and enhancing survivorship."
The findings and knowledge that City of Hope researchers are sharing at this year's conference include:
Parents’ ages at birth and risk of hormone-related cancer among women in the California Teachers Study [Link]
Menopausal hormone therapy and B-cell non-Hodgkin lymphoma (NHL) risk in the Los Angeles County NHL Case-control Study [Link]
Clinical cancer genetics in the next generation sequencing era [Link]
Cancer immunology for the nonimmunologist - tutorial [Link]
Novel implementation of cloud computing and mobile technology to transform data collection and management in cancer epidemiology [Link]
A comprehensive examination of breast cancer risk loci in African-American women [Link]
Knockdown ARID5A suppresses proliferation of LNCaP prostate cancer cell through the inhibition of global protein synthesis [Link]
NMR discovery and molecular-basis of small molecule inhibitors of STAT3 [Link]
High and moderate penetrance germline mutations in a number of genes are responsible for a small proportion of familial breast cancer risk in BRCAx families [Link]
Estrogen metabolites and colorectal cancer risk in postmenopausal women in the Breast and Bone Follow-up to the Fracture Intervention Trial (B~FIT) [Link]
Preventing hereditable cancers: treating the organ, the individual and their families [Link]
p53MVA therapy in patients with refractory gastrointestinal malignancies primes robust CD8+ T cell responses [Link]
Systemic delivery of STAT3 blocking/TLR9 activating oligodeoxynucleotides induces regression of mouse and human acute myeloid leukemia [Link]
Harmonization of next generation sequencing data within consortia for gene discovery in familial breast cancer [Link]
PKC/MARCKS pathway is a novel therapeutic target associated with breast cancer malignancy potential and paclitaxel resistance [Link]
A mutated ARID5B protein found in endometrial cancer has a deleterious function with longer half-life [Link]
Long-term consequences in cancer survivors [Link]
Role of gene repression by estrogen in invasiveness of breast cancer cells [Link]
Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced nonsmall cell lung cancer (NSCLC):CALGB 30801 (Alliance) [Link]
Role of pterostilbene on proliferation, invasion and migration in ovarian and uterine cancer cells [Link]
Learn more about City of Hope's research programs.